[
  {
    "ts": "2025-12-30T10:51:57+00:00",
    "headline": "Johnson & Johnson acquires Halda Therapeutics for $3.05bn",
    "summary": "The deal adds early-stage candidates for breast, lung, and other tumour types, using RIPTAC technology, to J&J’s pipeline.",
    "url": "https://www.pharmaceutical-technology.com/news/johnson-johnson-acquires-halda/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "8e55f30c-14b3-3814-b7b9-d3ef6a28d2e4",
      "content": {
        "id": "8e55f30c-14b3-3814-b7b9-d3ef6a28d2e4",
        "contentType": "STORY",
        "title": "Johnson & Johnson acquires Halda Therapeutics for $3.05bn",
        "description": "",
        "summary": "The deal adds early-stage candidates for breast, lung, and other tumour types, using RIPTAC technology, to J&J’s pipeline.",
        "pubDate": "2025-12-30T10:51:57Z",
        "displayTime": "2025-12-30T10:51:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/e98921a004d978bc920bb7a30d4e51aa",
          "originalWidth": 1440,
          "originalHeight": 816,
          "caption": "J&J anticipates earnings dilution in the fourth quarter of 2025 and into 2026. Credit: Skorzewiak/Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F9vTNyNzl7jPAiFIOWPkCQ--~B/aD04MTY7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/e98921a004d978bc920bb7a30d4e51aa.cf.webp",
              "width": 1440,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/47Jg2qpUYmm6ipTb.86sRg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/e98921a004d978bc920bb7a30d4e51aa.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/johnson-johnson-acquires-halda/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-acquires-halda-therapeutics-105157805.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-30T11:14:00+00:00",
    "headline": "The Zacks Analyst Blog Highlights International Business Machines, Analog Devices, Johnson & Johnson's, The Gap and Hewlett Packard Enterprise",
    "summary": "IBM leads a list of high-yield S&P 500 picks for 2026 as steady cash flow, dividends and AI exposure appeal amid market volatility.",
    "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-international-111400655.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "5c932b3c-6df2-3b51-a30f-6a0a1e3d2f52",
      "content": {
        "id": "5c932b3c-6df2-3b51-a30f-6a0a1e3d2f52",
        "contentType": "STORY",
        "title": "The Zacks Analyst Blog Highlights International Business Machines, Analog Devices, Johnson & Johnson's, The Gap and Hewlett Packard Enterprise",
        "description": "",
        "summary": "IBM leads a list of high-yield S&P 500 picks for 2026 as steady cash flow, dividends and AI exposure appeal amid market volatility.",
        "pubDate": "2025-12-30T11:14:00Z",
        "displayTime": "2025-12-30T11:14:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/58724708490e67ef1bafc8867f3885b5",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EtTE6Da360hUf5qCa.z9Gg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/58724708490e67ef1bafc8867f3885b5.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Mp0N.vzdPsVPORObsz6p6Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/58724708490e67ef1bafc8867f3885b5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-international-111400655.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-international-111400655.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IBM"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "HPE"
            },
            {
              "symbol": "ADI"
            },
            {
              "symbol": "GAP"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-30T14:35:00+00:00",
    "headline": "Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever",
    "summary": "Investors seeking reliable dividends will find that this trio of healthcare stocks offers an exciting combination of safety, growth, and income.",
    "url": "https://www.fool.com/investing/2025/12/30/got-500-3-dividend-paying-healthcare-stocks-to-buy/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "046ccbc5-34ca-3797-b1f6-7e8e0e1ab155",
      "content": {
        "id": "046ccbc5-34ca-3797-b1f6-7e8e0e1ab155",
        "contentType": "STORY",
        "title": "Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever",
        "description": "",
        "summary": "Investors seeking reliable dividends will find that this trio of healthcare stocks offers an exciting combination of safety, growth, and income.",
        "pubDate": "2025-12-30T14:35:00Z",
        "displayTime": "2025-12-30T14:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/c830d26d7c2cc23fd4a49d524598a557",
          "originalWidth": 1201,
          "originalHeight": 768,
          "caption": "The word dividends held up between a jar of coins and paper money.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OthKcIzL6TkkbKHvwUBOBA--~B/aD03Njg7dz0xMjAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/c830d26d7c2cc23fd4a49d524598a557.cf.webp",
              "width": 1201,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/z2kW.JPWiMfw_vfiQRAdoQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/c830d26d7c2cc23fd4a49d524598a557.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/30/got-500-3-dividend-paying-healthcare-stocks-to-buy/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/got-500-3-dividend-paying-143500428.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MDT"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-30T12:59:00+00:00",
    "headline": "3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains",
    "summary": "Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.",
    "url": "https://finance.yahoo.com/news/3-dividend-paying-pharma-stocks-125900443.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "5a92206d-fd62-3bd8-a9b7-102f498ce9f9",
      "content": {
        "id": "5a92206d-fd62-3bd8-a9b7-102f498ce9f9",
        "contentType": "STORY",
        "title": "3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains",
        "description": "",
        "summary": "Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.",
        "pubDate": "2025-12-30T12:59:00Z",
        "displayTime": "2025-12-30T12:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-dividend-paying-pharma-stocks-125900443.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-dividend-paying-pharma-stocks-125900443.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-30T23:09:28+00:00",
    "headline": "Johnson & Johnson (JNJ) Ends Mid-Stage Eczema Study After Missing Efficacy Bar",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with moderate to severe atopic dermatitis. The decision followed an interim analysis showing the treatment did not meet its […]",
    "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-ends-mid-230928013.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "aa59b3c7-50b4-3f74-ba4f-bfb6732d9053",
      "content": {
        "id": "aa59b3c7-50b4-3f74-ba4f-bfb6732d9053",
        "contentType": "STORY",
        "title": "Johnson & Johnson (JNJ) Ends Mid-Stage Eczema Study After Missing Efficacy Bar",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with moderate to severe atopic dermatitis. The decision followed an interim analysis showing the treatment did not meet its […]",
        "pubDate": "2025-12-30T23:09:28Z",
        "displayTime": "2025-12-30T23:09:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Johnson & Johnson (JNJ) Ends Mid-Stage Eczema Study After Missing Efficacy Bar",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qG_90ptmVmYmlFzMjoC0Yw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q3JcjOP_BI3o_9_ANEkK.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-ends-mid-230928013.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-ends-mid-230928013.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]